In the EPCORE DLBCL-3 study, fixed-duration epcoritamab monotherapy delivered deep, durable responses with manageable ...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE ® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging ...

Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or ...

A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, albeit with a high incidence of hematologic toxicity and infections. The ...

Epcoritamab plus chemoimmunotherapy achieved an 87% overall response rate in relapsed/refractory DLBCL patients, with 65% achieving complete response. The regimen offers a potential bridge to ASCT or ...

At the recent American Society of Hematology annual meeting, early data from the Mithic-FL1 Trial demonstrated impressive response rates with frontline mosunetuzumab (Lunsumio) in high-tumor-bulk ...

LAS VEGAS -- Patients with high-risk, treatment-unresponsive non-muscle invasive bladder cancer (NMIBC) had an unprecedented response rate and disease-free survival (DFS) with an investigational ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

(RTTNews) - AbbVie (ABBV) announced updated results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody ...

Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapy In vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion ...

Efti plus Keytruda and chemotherapy achieved a 60.8% ORR and 90.2% DCR in advanced NSCLC patients. The combination therapy showed improved ORR across all PD-L1 expression levels compared to historical ...